

Three Generations With ZEISS Refractive Laser Solutions: PRK, LASIK, and SMILE

Highlights from the ZEISS Satellite Symposium held in Copenhagen, Denmark, on Sept. 11, 2016, the 200th birthday of Carl Zeiss.

SMILE AT 7.5 YEARS: A TEST OVER TIME

Rupal Shah, MD, is Group Medical Director of New Vision Laser Centers-Centre for Sight, a large chain of refractive laser centers in India. She has performed more than 35,000 laser vision correction procedures and is one of the pioneers in the field of refractive lenticule extraction technique.

At the ESCRS in Copenhagen, Dr. Shah shared her experience with refractive lenticule extraction during the past 7.5 years, beginning with femtosecond lenticule extraction (FLEX) and including the current small incision lenticule extraction (SMILE) procedure.

She recently conducted long-term follow-up in patients who underwent FLEX or SMILE between August 2008 and May 2009.¹ Of the 132 patients who had undergone one of these two lenticule extraction techniques for myopia and myopic astigmatism with spherical equivalent of less than 10.00 D between August 2008 and May 2009, 30 had returned for an additional check-up for statistical reasons. These follow-ups occurred between April and May 2016, and the results were included in the study. At that time, all patients reported satisfaction with the procedure and said that they would recommend the procedure to their friends or relatives. Dryness or grittiness in their eyes and difficulties in driving at night were the only reported adverse effects (n = 6).

Dr. Shah concluded her presentation by saying, "SMILE has come a long way over the years, with better surgical techniques, faster laser, better energy parameters and an improved scan pattern. I think SMILE is here to stay, and we should all adopt it as quickly as possible."

US STUDY OF SMILE FOR MYOPIA AND MYOPIC ASTIGMATISM

Stephen G. Slade, MD, FACS, the National Medical Director of TLC Laser Eye Centers, in Houston, Texas, provided an overview of the study findings that resulted in the recent US FDA approval of ReLEx SMILE (ZEISS) for the correction of myopia.

The study outcomes included that more than 99% of study participants had $\geq 20/40$ UCVA at 12 months postoperatively (Figure 1) and that 70% had UCVA better than or equal to preoperative BCVA.²

"Predictability and stability were excellent," Dr. Slade said.

In addition to the efficacy data, Dr. Slade also summarized the safety data, which showed that all patients in the study had BCVA 20/40 or better beyond week 1. Further, 1 week following surgery, none of the eyes had lost 2 lines of vision. A total of 14 patients reported minor adverse events, but those resolved as well, Dr. Slade said.

Dr. Slade also gave a brief update on the ongoing study on SMILE for myopic astigmatism: "I am an investigator on that study, and I can tell you that we are quite happy with our results," he concluded.

SMILE FOR HYPEROPIA: SUCCESSFUL PILOT AND FIRST STUDY OUTCOMES

The details of several studies on the use of the ReLEx SMILE software for treating hyperopic patients (ZEISS) were presented by Kishore Raj Pradhan, MD, from the Tilganga Institute of Ophthalmology in Kathmandu, Nepal.

SMILE for hyperopia, Dr. Pradhan explained, is surgically similar to SMILE for myopia, and the lenticule dissection process is as easy to

High Rates of Post Operative UCVA $\geq 20/20$




Figure 1. The column on the left shows UCVA at 6 months postoperative and the column on the right shows UCVA at 12 months postoperative.

